Search Results - M. Gartland

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Cover Image

    Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study) by J. Van Wyk, F. Ajana, F. Bisshop, S. De Wit, Y. Osiyemi, J. Portilla, J. Routy, C. Wyen, M. Ait-Khaled, M. Nascimento, K. Pappa, R. Wang, J. Wright, A. Tenorio, B. Wynne, M. Aboud, M. Gartland, K. Smith, Y. El-Bahy

    Published 2020
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies by P. Cahn, J. Sierra Madero, J. Arribas, A. Antinori, R. Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, J. Sievers, C. Man, R. Urbaityte, M. Underwood, A. Tenorio, K. Pappa, B. Wynne, M. Gartland, M. Aboud, J. van Wyk, K. Smith, Y. El-Bahy

    Published 2020
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: